922 related articles for article (PubMed ID: 27895398)
1. Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.
Baird AC; Mallon D; Radford-Smith G; Boyer J; Piche T; Prescott SL; Lawrance IC; Tulic MK
World J Gastroenterol; 2016 Nov; 22(41):9104-9116. PubMed ID: 27895398
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis.
Wine E; Mack DR; Hyams J; Otley AR; Markowitz J; Crandall WV; Leleiko N; Muise AM; Griffiths AM; Turner D
J Crohns Colitis; 2013 Dec; 7(11):916-22. PubMed ID: 23339932
[TBL] [Abstract][Full Text] [Related]
3. Altered pattern of tumor necrosis factor-alpha production in peripheral blood monocytes from Crohn's disease.
Loganes C; Pin A; Naviglio S; Girardelli M; Bianco AM; Martelossi S; Tommasini A; Piscianz E
World J Gastroenterol; 2016 Nov; 22(41):9117-9126. PubMed ID: 27895399
[TBL] [Abstract][Full Text] [Related]
4. Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease.
Gibson DJ; Elliott L; McDermott E; Tosetto M; Keegan D; Byrne K; Martin ST; Rispens T; Cullen G; Mulcahy HE; Cheifetz AS; Moss AC; Robson SC; Doherty GA; Ryan EJ
Inflamm Bowel Dis; 2015 Dec; 21(12):2806-14. PubMed ID: 26332314
[TBL] [Abstract][Full Text] [Related]
5. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
[TBL] [Abstract][Full Text] [Related]
6. TLR activation pathways in HIV-1-exposed seronegative individuals.
Biasin M; Piacentini L; Lo Caputo S; Naddeo V; Pierotti P; Borelli M; Trabattoni D; Mazzotta F; Shearer GM; Clerici M
J Immunol; 2010 Mar; 184(5):2710-7. PubMed ID: 20124101
[TBL] [Abstract][Full Text] [Related]
7. Innate immunity alterations in idiopathic interstitial pneumonias and rheumatoid arthritis-associated interstitial lung diseases.
Papanikolaou IC; Boki KA; Giamarellos-Bourboulis EJ; Kotsaki A; Kagouridis K; Karagiannidis N; Polychronopoulos VS
Immunol Lett; 2015 Feb; 163(2):179-86. PubMed ID: 25540922
[TBL] [Abstract][Full Text] [Related]
8. Comparison of health-related quality of life and disability in ulcerative colitis patients following restorative proctocolectomy with ileal pouch-anal anastomosis versus anti-tumor necrosis factor therapy.
van Gennep S; Sahami S; Buskens CJ; van den Brink GR; Ponsioen CY; D'Hoore A; de Buck van Overstraeten A; van Assche G; Ferrante M; Vermeire S; Bemelman WA; D'Haens GR; Löwenberg M
Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):338-344. PubMed ID: 27902515
[TBL] [Abstract][Full Text] [Related]
9. Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy.
Dahlén R; Magnusson MK; Bajor A; Lasson A; Ung KA; Strid H; Öhman L
Scand J Gastroenterol; 2015; 50(9):1118-26. PubMed ID: 25877762
[TBL] [Abstract][Full Text] [Related]
10. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients.
Thapa SD; Hadid H; Usman M; Imam W; Hassan A; Schairer J; Jafri SM; Kaur N
Dig Dis Sci; 2016 Jan; 61(1):230-7. PubMed ID: 26511478
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases.
Billmeier U; Dieterich W; Neurath MF; Atreya R
World J Gastroenterol; 2016 Nov; 22(42):9300-9313. PubMed ID: 27895418
[TBL] [Abstract][Full Text] [Related]
13. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
Ebert EC; Das KM; Mehta V; Rezac C
Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
[TBL] [Abstract][Full Text] [Related]
14. Histamine Receptor 2 is Required to Suppress Innate Immune Responses to Bacterial Ligands in Patients with Inflammatory Bowel Disease.
Smolinska S; Groeger D; Perez NR; Schiavi E; Ferstl R; Frei R; Konieczna P; Akdis CA; Jutel M; OʼMahony L
Inflamm Bowel Dis; 2016 Jul; 22(7):1575-86. PubMed ID: 27271490
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor expression and function in type I bipolar disorder.
Wieck A; Grassi-Oliveira R; do Prado CH; Viola TW; Petersen LE; Porto B; Teixeira AL; Bauer ME
Brain Behav Immun; 2016 May; 54():110-121. PubMed ID: 26795430
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol enhances TNF-α production in human monocytes upon bacterial stimulation.
Gualdoni GA; Kovarik JJ; Hofer J; Dose F; Pignitter M; Doberer D; Steinberger P; Somoza V; Wolzt M; Zlabinger GJ
Biochim Biophys Acta; 2014 Jan; 1840(1):95-105. PubMed ID: 24035785
[TBL] [Abstract][Full Text] [Related]
17. Activation of myeloid dendritic cells, effector cells and regulatory T cells in lichen planus.
Domingues R; de Carvalho GC; Aoki V; da Silva Duarte AJ; Sato MN
J Transl Med; 2016 Jun; 14(1):171. PubMed ID: 27286889
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma?
Fernandes P; MacSharry J; Darby T; Fanning A; Shanahan F; Houston A; Brint E
Clin Exp Immunol; 2016 Mar; 183(3):358-68. PubMed ID: 26462859
[TBL] [Abstract][Full Text] [Related]
19. Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus.
Wong CK; Wong PT; Tam LS; Li EK; Chen DP; Lam CW
Clin Exp Immunol; 2010 Jan; 159(1):11-22. PubMed ID: 19843090
[TBL] [Abstract][Full Text] [Related]
20. Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.
O'Connell J; Rowan C; Stack R; Harkin G; Parihar V; Chan G; Breslin N; Cullen G; Dunne C; Egan L; Harewood G; Leyden J; MacCarthy F; MacMathuna P; Mahmud N; McKiernan S; McNamara D; Mulcahy H; Murray F; O'Connor A; O'Toole A; Patchett S; Ryan B; Sheridan J; Slattery E; Doherty G; Kevans D
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1019-1026. PubMed ID: 29878945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
